000			03050nam a22004095i 4500
003			ESmaUEC
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
040			_aES-MaUEC _bspa _cES-MaUEC
336			_aTexto _btxt _2rdacontent
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996
999			_c107004 _d107004 _x1
001			107004
005			20230214040201.0
008			180328s2018 gw | s |||| 0|eng d
020			_a9783319679327
024	7		_a10.1007/978-3-319-67932-7 _2doi
050		4	_aRC271.C5 2018 EB
245	1	0	_aResistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways _cedited by Yosef Yarden, Moshe Elkabets.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2018
300			_a1 recurso en línea (XX, 242 páginas 22 ilustraciones a color)
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aResistance to Targeted Anti-Cancer Therapeutics _x2196-5501 _v15
490	0		_aBiomedical and Life Sciences (Springer-11642)
505	0		_aResistance of colorectal tumors to anti-EGFR antibodies -- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK -- Mechanisms of action and resistance of trastuzumab in breast cancer -- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis -- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge -- Mechanisms of resistance to PI3K and AKT inhibitors -- Sensitivity and resistance to BH3 mimetics in cancer therapy -- Resistance mechanisms to cyclin-dependent kinase inhibitors -- Resistance to inhibitors of angiogenesis.
520	3		_aThis volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
650		7	_aCélulas cancerosas _9146156 _2embne
650		7	_aAntineoplásicos _2embne _9405304
700	1		_aYarden, Yosef. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/nb99166168 _1http://viaf.org/viaf/19181455 _984709
700	1		_aElkabets, Moshe. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _1http://viaf.org/viaf/160861988
776	0	8	_iEdición impresa: _z9783319679303
776	0	8	_iEdición impresa: _z9783319679310
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-67932-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_aSI _b04/2019 _cm _dz _ek _feng _ggw _h0